2 Pharmaceutical Stocks Set to Rebound in 2026

Novo Nordisk and Merck are positioned for a potential rebound in 2026 driven by product approvals, label expansions and late‑stage clinical progress: Novo Nordisk secured a Wegovy label expansion for metabolic dysfunction‑associated steatohepatitis, won approval for an oral Wegovy formulation, is awaiting approval for next‑gen CagriSema, and is advancing Amycretin in phase 3, supporting expectations for stronger financial results. Merck showed late‑2025 momentum with a phase‑2 win for Winrevair, progress on CD388 (a long‑acting antiviral for influenza), and commercial rollout of a subcutaneous Keytruda formulation that could help mitigate the 2028 patent cliff, though HPV vaccine weakness in China will temper near‑term sales.

Analysis

Market structure: Winners are NVO (Novo Nordisk) and MRK (Merck) if CagriSema, oral Wegovy and Keytruda subcutaneous scale — these extend pricing power in obesity and oncology and can recover 200–400bps of share over 12 months versus peers. Losers include current market-share leaders in GLP-1 space (e.g., LLY) and legacy vaccine providers exposed to China demand (pressure on MRK's Gardasil sales). Supply/demand tightness for obesity therapies should keep implied vols elevated (options), while successful launches reduce sovereign/bond safe‑haven flows if healthcare equities re-rate.

Risk assessment: Tail risks include FDA/EMA non-approval or label restrictions for CagriSema/Amycretin, Keytruda biosimilar entry around 2028 producing a multi-billion-dollar revenue gap, or production bottlenecks for new oral formulations; each could wipe 10–30% off relevant drug-year revenues. Near-term (30–90 days) risk centers on regulatory milestones and quarterly sales/volume cadence; medium-term (6–18 months) on commercial uptake and payer coverage; long-term (2028+) on patent cliff mitigation. Hidden dependencies: Chinese vaccine demand, payer step edits, and manufacturing scale-up timelines—monitor supply agreements and country-level reimbursement decisions.

Trade implications: Direct: establish a 2–3% long position in NVO to capture 6–12 month approval/commercialization upside and hedge with buying Jan 2027 LEAP calls equal to ~25% of equity exposure to cap downside. For MRK, initiate a 1–2% position via a 9–12 month call spread to monetize clinical-readout optionality (Winrevair/CD388) while limiting carry. Pair trade: long NVO / short LLY (0.5–1% net) to play potential mean reversion if NVO regains share; consider selling 60–90 day put spreads on NVO to collect premium into expected post-approval dips.

Contrarian angles: Consensus may underweight payer resistance — successful approvals do not guarantee broad access; if payors impose strict step therapy, volume could land 20–40% below forecasts. Conversely, the market may underprice Merck’s ability to monetize subQ Keytruda and newer antivirals: a successful CD388 launch could reframe flu prophylaxis TAM and be a multi-year re-rating trigger. Historical parallels: oncology patent cliffs (e.g., small‑molecule comps) show companies that proactively launch adjacent formulations can preserve 30–60% of incumbent revenue; failure to scale commercial operations is the main unintended consequence to watch.

Key Decisions for Investors

• Establish a 2–3% long position in NVO (Novo Nordisk) within 30 days to catch potential share recovery from oral Wegovy and CagriSema; allocate ~25% of that exposure to Jan 2027 LEAP calls to create asymmetric upside while capping downside.
• Initiate a 1–2% tactical long in MRK (Merck) via a 9–12 month call spread (buy calls / sell higher strike calls) sized to cap premium outlay; target clinical catalysts Winrevair/CD388 readouts and monitor Keytruda subQ uptake metrics quarterly.
• Implement a pair trade: long NVO / short LLY (Eli Lilly) sized 0.5–1% net to express mean-reversion in obesity-market share; rebalance if NVO regains >300bps share or if LLY posts >5% QoQ revenue acceleration.
• Sell 60–90 day NVO put spreads (cash-secured) on 5–10% notional to collect premium into expected post-approval volatility, with strike widths sized to limit assignment risk to levels comfortable as a 2–3% position.
• Reduce cyclical healthcare exposure funded by these buys by 1–2% if MRK/Gardasil China weakness persists after the next quarterly report; specifically cut positions in vaccine-exposed small caps if Chinese demand remains >20% below prior-year levels.